Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada.

ABSTRACT:

Introduction

New requirements in Canada's pricing processes for patented drugs may exacerbate delays in regulatory and reimbursement reviews. This study seeks to better understand the impact of any additional delays on non-small cell lung cancer (NSCLC) patients by measuring the following: (a) durations and outcomes of regulatory and reimbursement reviews of NSCLC drugs in Canada and reference countries; (b) delays in Canada's reviews of three NSCLC drugs (nivolumab, afatinib, and pemetrexed [NAP]); and (c) estimating clinical, patient, and economic impacts of delays in Canada's reviews on access to NAP.

Methods

Information from the Context Matters database and the literature (2005-2020) was used to evaluate the durations and outcomes of reimbursement reviews of NSCLC drugs

SUBMITTER: Vanderpuye-Orgle J 

PROVIDER: S-EPMC8886863 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature